Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07447817 · ClinicalTrials.gov registry record · Phase 2
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
A Phase 2 study, sponsored by John Mascarenhas.
- Not yet
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT07447817 is a Phase 2 study that has not yet begun recruiting, run by John Mascarenhas. The registered enrollment target is 26 participants.
The verdict
NCT07447817, a Phase 2 study, has not yet begun recruiting, sponsored by John Mascarenhas.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.
Interventions
- DRUG Selinexor
- DRUG Pacritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2026-05-04 |
| Est. Completion | 2030-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07447817
The ClinicalTrials.gov registry entry for NCT07447817 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Mascarenhas, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selinexor is the first listed.
NCT07447817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07447817 about?
NCT07447817 is a clinical study titled "Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias". This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.
What is the current status of trial NCT07447817?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2026-05-04. Estimated completion is 2030-05-24.
What interventions are being tested in trial NCT07447817?
The interventions under investigation include: Selinexor (DRUG), Pacritinib (DRUG).
Who is sponsoring clinical trial NCT07447817?
This trial is sponsored by John Mascarenhas, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.